Healthy China 2030 reforms: A balance of opportunities and risks for investors

Country has introduced healthcare reforms

clock • 4 min read
Baijing Yu of Comgest
Image:

Baijing Yu of Comgest

With the 'Healthy China 2030' programme underway, the Chinese government is aiming to improve healthcare quality and affordability across the nation through reformed legislation and institutional reorganisation.

These reforms are transforming the country's drug innovation and healthcare ecosystem, offering enticing opportunities for investors although there are some risks to watch out for. Supported by an ageing population, rising disposable income and commercial insurance, healthcare spending in China remains robust and we expect it to grow at a 10% compound annual growth rate (CAGR) over the next 10 years. The recent years' reforms are enabling more innovative drugs and therapies to be approved faster than ever before. China now has an increasingly competitive medical devices and biotech...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot